BACKGROUND: The prevalence and predictors of nonalcoholic fatty liver disease (NAFLD) in human immunodeficiency virus (HIV)-infected highly active antiretroviral therapy-experienced patients and the association of NAFLD with risk of cardiovascular disease and subclinical atherosclerosis are unknown. METHODS: We performed a cross-sectional observational study. NAFLD was defined by liver-spleen attenuation values of <1.1 on computed tomography in persons who had neither evidence of chronic viral hepatitis nor a significant history of alcohol consumption. RESULTS: We enrolled 225 patients; 163 (72.4%) were men. Mean (+/-SD) HIV infection duration was 145 +/- 60 months, and mean (+/-SD) body mass index (calculated as weight in kilograms divided by the square of height in meters) was 23.75 +/- 3.59. NAFLD was diagnosed in 83 patients (36.9% of the total cohort). The following variables were significantly associated with NAFLD in univariate analyses: sex, waist circumference, body mass index, cumulative exposure to nucleoside reverse-transcriptase inhibitors, visceral adipose tissue, homeostasis model assessment of insulin resistance index, serum alanine and aspartate aminotransferase levels, and ratios of total serum cholesterol to high-density lipoprotein cholesterol. Coronary artery calcium scores and a diagnosis of diabetes were not associated with NAFLD. In multivariable logistic regression analyses, factors associated (P<0.001) with NAFLD were higher serum alanine to aspartate ratio (odds ratio, 4.59; 95% confidence interval, 2.09-10.08), male sex (odds ratio, 2.49; 95% confidence interval, 1.07-5.81), greater waist circumference (odds ratio, 1.07; 95% confidence interval, 1.03-1.11), and longer nucleoside reverse-transcriptase inhibitor exposure (odds ratio, 1.12 per year of exposure; 95% confidence interval, 1.03-1.22). CONCLUSIONS: NAFLD is common among HIV-infected persons who have the traditional risk factors for NAFLD (elevations in serum alanine level, male sex, and increased waist circumference) apparent. Exposure to nucleoside reverse-transcriptase inhibitors was an independent risk factor for NAFLD, with an 11% increase in the odds ratio for each year of use.
Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors / Guaraldi, Giovanni; Squillace, N.; Stentarelli, Chiara; Orlando, Gabriella; D'Amico, Roberto; Ligabue, Guido; Fiocchi, Federica; Zona, Stefano; Loria, Paola; Esposito, Roberto; Palella, F.. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - STAMPA. - 47(2008), pp. 250-257. [10.1086/589294]
Data di pubblicazione: | 2008 | |
Titolo: | Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors | |
Autore/i: | Guaraldi, Giovanni; Squillace, N.; Stentarelli, Chiara; Orlando, Gabriella; D'Amico, Roberto; Ligabue, Guido; Fiocchi, Federica; Zona, Stefano; Loria, Paola; Esposito, Roberto; Palella, F. | |
Autore/i UNIMORE: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1086/589294 | |
Rivista: | ||
Volume: | 47 | |
Pagina iniziale: | 250 | |
Pagina finale: | 257 | |
Codice identificativo ISI: | WOS:000256905000018 | |
Codice identificativo Scopus: | 2-s2.0-46349092154 | |
Codice identificativo Pubmed: | 18532884 | |
Citazione: | Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors / Guaraldi, Giovanni; Squillace, N.; Stentarelli, Chiara; Orlando, Gabriella; D'Amico, Roberto; Ligabue, Guido; Fiocchi, Federica; Zona, Stefano; Loria, Paola; Esposito, Roberto; Palella, F.. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - STAMPA. - 47(2008), pp. 250-257. [10.1086/589294] | |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
NAFLD_in_HIV.pdf | Post-print dell'autore (bozza post referaggio) | Administrator Richiedi una copia |
Pubblicazioni consigliate

I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris